DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Author: Vanessa Ngan, Staff Writer, 2012.
Ecamsule is a benzylidene derivative and is a chemical substance that is used in sunscreen products. It is able to absorb the full spectrum of UVA rays and some UVB rays. It was developed and patented by L’Oreal and approved for use in Europe in 1991. In 2006, the FDA approved its use in the US.
Ecamsule has greater photostability when compared with avobenzone. Although ecamsule does not degrade as quickly as avobenzone when exposed to hours of sun, it does breakdown and lose 40% of its protective properties. To improve its UV coverage and photostability ecamsule has been formulated with avobenzone and octocrylene. This product is marketed in the US as Anthelios SX and some tests show it to be effective in vitro for as much as 5 hours.
Because ecamsule is relatively new to the sunscreen market there are no studies available regarding its long term use. Safety and efficacy studies performed for FDA approval showed that ecamsule was well tolerated and any side effects were infrequent and mild. The most common reactions were dermatitis, dry skin, acne, itching, redness and skin discomfort. Further long-term human safety studies are required.
Formula: C28H34O8 S2
CAS number: 92761-26-7
Cross reactions: unknown
See the DermNet NZ bookstore
© 2019 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.